Abstract
Bladder cancer is a heterogeneous disease with a variable natural history. At one end of the spectrum, low-grade Ta tumors have a low progression rate and require initial endoscopic treatment and surveillance but rarely present a threat to the patient. At the other extreme, high-grade tumors have a high malignant potential associated with significant progression and cancer death rates. In the Western world, bladder cancer is the fourth most common malignancy in men and the eighth most common in women. In Europe and the United States, bladder cancer accounts for 5% to 10% of all malignancies in men. The risk of developing bladder cancer at T1. Current studies do not support the routine screening for bladder cancer. However, prospective long-term studies are required to evaluate the benefits of bladder cancer screening, particularly in those at high risk. After assessing all available evidence, the Epidemiology and Diagnosis Committee has made recommendations on various diagnostic issues, including pathologic evaluation, urinary cytology, and imaging studies. Optimal resection techniques, role of repeat transurethral resection in high-grade T1 tumors, random bladder biopsy, and prostatic urethral biopsy are discussed, and appropriate recommendations are made according to the strength of available evidence.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 4-34 |
| Number of pages | 31 |
| Journal | Urology |
| Volume | 66 |
| Issue number | 6 SUPPL. 1 |
| DOIs | |
| State | Published - Dec 2005 |
Fingerprint
ASJC Scopus subject areas
- Urology
Cite this
Bladder cancer : Epidemiology, staging and grading, and diagnosis. / Kirkali, Ziya; Chan, Theresa; Manoharan, Murugesan; Algaba, Ferran; Busch, Christer; Cheng, Liang; Kiemeney, Lambertus; Kriegmair, Martin; Montironi, R.; Murphy, William M.; Sesterhenn, Isabell A.; Tachibana, Masaaki; Weider, Jeff.
In: Urology, Vol. 66, No. 6 SUPPL. 1, 12.2005, p. 4-34.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Bladder cancer
T2 - Epidemiology, staging and grading, and diagnosis
AU - Kirkali, Ziya
AU - Chan, Theresa
AU - Manoharan, Murugesan
AU - Algaba, Ferran
AU - Busch, Christer
AU - Cheng, Liang
AU - Kiemeney, Lambertus
AU - Kriegmair, Martin
AU - Montironi, R.
AU - Murphy, William M.
AU - Sesterhenn, Isabell A.
AU - Tachibana, Masaaki
AU - Weider, Jeff
PY - 2005/12
Y1 - 2005/12
N2 - Bladder cancer is a heterogeneous disease with a variable natural history. At one end of the spectrum, low-grade Ta tumors have a low progression rate and require initial endoscopic treatment and surveillance but rarely present a threat to the patient. At the other extreme, high-grade tumors have a high malignant potential associated with significant progression and cancer death rates. In the Western world, bladder cancer is the fourth most common malignancy in men and the eighth most common in women. In Europe and the United States, bladder cancer accounts for 5% to 10% of all malignancies in men. The risk of developing bladder cancer at T1. Current studies do not support the routine screening for bladder cancer. However, prospective long-term studies are required to evaluate the benefits of bladder cancer screening, particularly in those at high risk. After assessing all available evidence, the Epidemiology and Diagnosis Committee has made recommendations on various diagnostic issues, including pathologic evaluation, urinary cytology, and imaging studies. Optimal resection techniques, role of repeat transurethral resection in high-grade T1 tumors, random bladder biopsy, and prostatic urethral biopsy are discussed, and appropriate recommendations are made according to the strength of available evidence.
AB - Bladder cancer is a heterogeneous disease with a variable natural history. At one end of the spectrum, low-grade Ta tumors have a low progression rate and require initial endoscopic treatment and surveillance but rarely present a threat to the patient. At the other extreme, high-grade tumors have a high malignant potential associated with significant progression and cancer death rates. In the Western world, bladder cancer is the fourth most common malignancy in men and the eighth most common in women. In Europe and the United States, bladder cancer accounts for 5% to 10% of all malignancies in men. The risk of developing bladder cancer at T1. Current studies do not support the routine screening for bladder cancer. However, prospective long-term studies are required to evaluate the benefits of bladder cancer screening, particularly in those at high risk. After assessing all available evidence, the Epidemiology and Diagnosis Committee has made recommendations on various diagnostic issues, including pathologic evaluation, urinary cytology, and imaging studies. Optimal resection techniques, role of repeat transurethral resection in high-grade T1 tumors, random bladder biopsy, and prostatic urethral biopsy are discussed, and appropriate recommendations are made according to the strength of available evidence.
UR - http://www.scopus.com/inward/record.url?scp=30044441045&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=30044441045&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2005.07.062
DO - 10.1016/j.urology.2005.07.062
M3 - Article
C2 - 16399414
AN - SCOPUS:30044441045
VL - 66
SP - 4
EP - 34
JO - Urology
JF - Urology
SN - 0090-4295
IS - 6 SUPPL. 1
ER -